Applying peptide antigens onto bare skin: Induction of humoral and cellular immune responses and potential for vaccination

Journal of Controlled Release

Volumn 85, Issue 1-3, 2002, Pages 27-34

  Partidos, Charalambos D ^a   Beignon, Anne Sophie ^a   Brown, Fred ^b   Kramer, Ed ^b   Briand, Jean Paul ^a   Muller, Sylviane ^a  

^a CNRS   (France)

^b Animal Disease Center   (United States)

Author keywords

Adjuvants; Skin immunisation; Synthetic peptides; Vaccines

Indexed keywords

ANTIBODY; CD4 ANTIGEN; GANGLIOSIDE GM1; PEPTIDE; PROTEIN VP1; VACCINE; ANTIGEN;

ADJUVANT THERAPY; CELLULAR IMMUNITY; DRUG DELIVERY SYSTEM; FOOT AND MOUTH DISEASE; HUMORAL IMMUNITY; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN; T LYMPHOCYTE; VACCINATION; ANIMAL; ANTIBODY PRODUCTION; DRUG EFFECT; HUMAN; IMMUNOLOGY; METABOLISM;

ANIMALS; ANTIBODY FORMATION; ANTIGENS; HUMANS; IMMUNITY, CELLULAR; PEPTIDES; SKIN; VACCINES;

EID: 0037073631     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(02)00268-7     Document Type: Review

References (46)

1. André F.E. The future of vaccines, immunisation concepts and practice. Vaccine. 19:2001;2206-2209.
2. Jodar L., Duclos P., Milstien J.B., Griffiths E., Aguado M.T., Clements C.J. Ensuring vaccine safety in immunisation programmes - a WHO perspective. Vaccine. 19:2001;1594-1605.
3. Jacobson R.M., Swan A., Adegbenro A., Ludington S.L., Wollan P.C., Poland G.A. Making vaccines more acceptable-methods to prevent and minimise pain and other common adverse events associated with vaccines. Vaccine. 19:2001;2418-2427.
4. Kane A., Lloyd J., Zaffran M., Simonsen L., Kane M. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: Model-based regional estimates. Bull. WHO. 77:1999;801-807.
5. State of the World's Vaccines and Immunisation. World Health Organisation/United Nations Children's Fund, Geneva, 1996, p. 159.
6. Reeler A.V., Simonsen L. Unsafe injections, fatal injections. Children's Vaccine Programme. May:2000;1-8.
7. J. Lloyd. Technologies for Vaccine Delivery in the 21st Century. WHO/V&B/00.35, 2000, pp. 1-25.
8. Potera C. Making needles needles. MIT Mag. Innovation Technol. Sept./Oct. 1998;67-70.
9. Partidos C.D., Beignon A.-S., Semetey V., Briand J.-P., Muller S. The bare skin and the nose as non-invasive routes for administering peptide vaccines. Vaccine. 19:2001;2708-2715.
10. Partidos C.D. Intranasal vaccines: forthcoming challenges. Pharm. Sci. Technol. Today. 3:2000;273-281.
11. Glenn G.M., Rao M., Matyas G.R., Alving C.R. Skin immunisation made possible by cholera toxin. Nature. 391:1998;851.
12. Roop D. Defects in the barrier. Science. 267:1995;474-475.
13. Franz T.J., Lehman P.A. The skin as a barrier: structure and function. Kydonieus A.F., Wille J.J. Biochemical Modulation of Skin Reactions: Transdermals, Topicals, Cosmetics. 2000;15-33 CRC Press, Boca Raton, FL.
14. Bos J.D., Kapsenberg M.L. The skin immune system. Its cellular constituents and their interactions. Immunol. Today. 14:1993;75-78.
15. Streilein J.W. Skin-associated lymphoid tissues (SALT): origins and functions. J. Invest. Dermatol. 80:1983;12s-16s.
16. Uchi H., Terao H., Koga T., Furue M. Cytokines and chemokines in the epidermis. J. Dermatol. Sci. 24:2000;s29-s38.
17. Williams I.R., Kupper T.S. Immunity at the surface:homeostatic mechanisms of the skin immune system. Life Sci. 58:1996;1485-1507.
18. Wang B., Amerio P., Sauder D.N. Role of cytokines in epidermal Langerhans cell migration. J. Leukoc. Biol. 66:1999;33-39.
19. Bos J.D., Meinardi M.M.H.M. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp. Dermatol. 9:2000;165-169.
20. Glenn G.M., Scharton-Kersten T., Vassell R., Mallett C.P., Hale T.L., Alving C.R. Transcutaneous immunisation with cholera toxin protects mice against lethal mucosal toxin challenge. J. Immunol. 161:1998;3211-3214.
21. Scharton-Kersten T., Glenn G.M., Vassell R., Yu J.-M., Walwender D., Alving C.R. Principles of transcutaneous immunisation using cholera toxin as an adjuvant. Vaccine. 17:1999;S37-43.
22. Glenn G.M., Scharton-Kersten T., Vassell R., Matyas G.R., Alving C.R. Transcutaneous immunisation with bacterial ADP-ribosylating exotoxins as antigens and adjuvants. Infect. Immun. 67:1999;1100-1106.
23. Scharton-Kersten T., Yu J.-M., Vassell R., O'Hagan D., Alving C.R., Glenn G.M. Transcutaneous immunisation with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. Infect. Immun. 68:2000;5306-5313.
24. Beignon A.-S., Briand J.-P., Muller S., Partidos C.D. Immunisation onto bare skin with heat-labile enterotoxin of Escherichia coli enhances immune responses to co-administered protein and peptide antigens and protects mice against lethal toxin challenge. Immunology. 102:2001;344-351.
25. Glenn G.M., Scharton-Kersten T., Alving C.R. Advances in vaccine delivery: transcutaneous immunisation. Exp. Opin. Invest. Drugs. 8:1999;797-805.
26. Fan H., Lin Q., Morrissey G.R., Khavari P.A. Immunisation via hair follicles by topical application of naked DNA to normal skin. Nat. Biotech. 17:1999;870-872.
27. Glenn G.M., Taylor D.N., Li X., Frankel S., Montemarano A., Alving C.R. Transcutaneous immunisation: a human vaccine delivery strategy using a patch. Nat. Med. 6:2000;1403-1406.
28. Chen D., Colditz I.G., Glenn G.M., Tsonis C.G. Induction of systemic immune responses in sheep by topical application of cholera toxin to skin. Vet. Immunol. Immunopathol. 77:2000;191-199.
29. Hammond S.A., Tsonis C., Sellins K., Rushlow K., Scharton-Kersten T., Colditz I., Glenn G.M. Transcutaneous immunisation of domestic animals:opportunities and challenges. Adv. Drug Deliv. Rev. 43:2000;45-55.
30. El-Ghorr A.A., Williams R.M., Heap C., Norval M. Transcutaneous immunisation with herpes simplex virus stimulates immunity in mice. FEMS Immunol. Med. Microbiol. 29:2000;255-261.
31. Magnusson B.M., Walters K.A., Roberts M.S. Veterinary drug delivery: potential for skin penetration enhancement. Adv. Drug. Deliv. Rev. 50:2001;205-227.
32. Braun M.C., He J., Wu C.-Y., Kelsall B.L. Cholera toxin suppresses interleukin IL-12 production and IL-12 receptor β1 and β2 chain expression. J. Exp. Med. 189:1999;541-552.
33. Gagliardi M.C., Sallustro F., Marinaro M., Langenkamp A., Lanzavecchia A., DeMagistris M.T. Cholera toxin induces maturation of human dendritic cells and licences them for Th2 priming. Eur. J. Immunol. 30:2000;2394-2403.
34. Van Regenmortel M.H.V. The recognition of proteins and peptides by antibodies. J. Immunoassays. 21:2000;85-108.
35. Leist T.P., Cobbold S.P., Waldmann H., Aguet M., Zinkernagel R.M. Functional analysis of T lymphocyte subsets in antiviral host defence. J. Immunol. 138:1987;2278-2281.
36. + cytotoxic T cell responses during chronic viral infection. J. Virol. 68:1994;8056-8063.
37. Mosmann T.R., Coffman R.L. Th1 and Th2 cells:different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:1989;145-173.
38. Barchet W., Oehen S., Klenerman P., Wodarz D., Bocharov G., Lloyd A.L., Nowak M.A., Hengartner H., Zinkernagel R.M., Ehl S. Direct quantitation of rapid elimination of viral antigen-positive lymphocytes by antiviral CD8(+) T cells in vivo. Eur. J. Immunol. 30:2000;1356-1363.
39. + T-cells. Immunology. 105:2002;204-214.
40. Walker P.S., Scharton-Kersten T., Krieg A.M., Love-Homan L., Rowton E.D., Udey M.C., Vogel J.C. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms. Proc. Natl. Acad. Sci. USA. 96:1999;6970-6975.
41. Bohle B., Jahn-Schmid B., Maurer D., Kraft D., Ebner C. Oligodeoxynucleotides containing CpG motifs induce IL-12, IL-18 and IFN-gamma production in cells from allergic individuals and inhibit IgE synthesis in vitro. Eur. J. Immunol. 29:1999;2344-2353.
42. Seo N., Tokura Y., Nishijima T., Hashizume H., Furukawa F., Takigawa M. Percutaneous peptide immunisation via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis. Proc. Natl. Acad. Sci. USA. 97:2000;371-376.
43. Bittle J.L., Houghten R.A., Alexander H., Shinnick T.M., Sutcliffe J.G., Lerner R.A., Rowlands D.J., Brown F. Protection against FMDV by immunisation with a chemically synthesised peptide predicted from the viral nucleotide sequence. Nature. 298:1982;30-37.
44. Spangler B.D. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol. Rev. 56:1992;622-647.
45. Faldvari M. Non-invasive administration of drugs through the skin: challenges in delivery system design. Pharm. Sci. Technol. Today. 3:2000;417-425.
46. Babiuk S., Baca-Estrada M., Babiuk L.A., Ewen C., Foldvari M. Cutaneous vaccination: the skin as an immunologically active tissue and the challenge of antigen delivery. J Control. Release. 66:2000;199-214.